

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Wilson

Confirmation No.: 1884

App. No.: 10/713,860

Group Art Unit: 1614

Filed: 11/17/03

Examiner: HILL, M.

For: METHODS AND FORMULATIONS OF USING A1 ADENOSINE
ANTAGONISTS AND P2X PURIONCEPTOR ANTAGONISTS FOR THE
TREATMENT AND PREVENTION OF IMMUNE SYSTEM DISORDERS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97**

Attached is a list of documents on form PTO-1449 on Form PTO-1449 listing several documents that were first cited in the European Search Report for the corresponding European Application Number 02736991.7 not more than three months prior to the filing of this Statement.

In this regard, Applicant notes that the European Search Report was not received by any individual designated by 37 CFR 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

The Search Report is enclosed along with any cited foreign patent documents and non-patent literature documents in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

In re: Wilson
Appli. No.: 10/713,860
Filed: 11/17/03
Page 2



Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michelle L. Cunningham".

Michelle L. Cunningham
Registration No. 51,072

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

RTA01/2201287v1

"Express Mail" mailing label number EV395777921US
Date of Deposit March 24, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

A handwritten signature in black ink, appearing to read "Pamela Lockley".

Pamela Lockley

Substitute for form 1449/PTO
(Revised 07/2005)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/713,860
Filing Date 11/17/03
First Named Inventor Wilson
Group Art Unit 1614
Examiner Name Hill, M.
Attorney Docket Number 049542/284259

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	1	WO 99/64418	12-16-1999	NOVARTIS		
	2	WO 99/21555	05-06-1999	TAKEDA CHEMICAL INDUSTRIES		
	3	WO 01/74811 A2	10-11-2001	TAKEDA CHEMICAL INDUSTRIES		

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	4	LAMBRECHT, G., "Design and Pharmacology of Selective P ₂ -Purinoceptor Antagonists," <i>Journal of Autonomic Pharmacology</i> , 1996, pp. 341-344, Vol. 16(6).	
	5	LAMBRECHT, G., "Agonists and Antagonists Acting at P2X Receptors: Selectivity Profiles and Functional Implications," <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , 2000, pp. 340-350, Vol. 362.	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.